Neurofibromatosis Therapeutic Acceleration Program
@ntapresearch
Followers
163
Following
103
Media
45
Statuses
96
Accelerating the development of effective therapeutics for plexiform and cutaneous neurofibromas
Baltimore, Maryland
Joined May 2023
RT @IUCancerCenter: The cancer center’s D. Wade Clapp, MD, and colleagues have published their latest findings in the Journal of Neuro-Onco….
0
3
0
RT @PennNSG: We're excited to have @BettegowdaMDPHD from @HopkinsNsurg join us this week for our #Neurosurgery Grand Rounds! .
0
8
0
Congrats! Excited to see the next generation of scientists driving discovery for the NF1 community. Make this summer count! 🔬🧬. #NF1 #Research #FutureScientists #SummerInterns #TeamScience.
Please join us in welcoming our amazing summer interns to BRIDGE Lab! . We’re thrilled to have Tali, Catalina, and Annetta join the team. Each of them brings curiosity, enthusiasm, and fresh perspective to our work, and we’re excited to learn and grow together this summer.
0
0
0
Pipeline of experts advances discovery in neurofibromatosis via @HubJHU Accepting applications now for the 2026 Francis Collins Scholars Program. #EndNF #NFResearch.
0
1
2
RT @Sagebio: 🧬 Help Advance Genomic Interpretation—Join a CAGI7 Challenge!. Sage Bionetworks is excited to support the recently launched CA….
0
2
0
Grateful for Dr. Karen Horton’s inspiring leadership at @Hopkins_Rad 🙌 and the Reames family for their support —she’s shaping the next generation of radiology leaders. #MedicalEducation #Radiology #FutureOfMedicine #ThankYou.
Karen Horton, MD, leads @Hopkins_Rad with a vision for innovation in care, education, and research. With support from the Reames family, she’s ensuring trainees are prepared for the radiology of the future. #FacultyFriday. Read more:
0
1
3
Are you an early-career clinician scientist passionate about transforming care for people with NF1? The Francis Collins Scholars Program is a prestigious, fully funded opportunity - now accepting applications. Learn more at
0
3
3
Enrollment Success! NTAP’s Natural History Study on cNFs has enrolled 495 participants. With goals to identify populations @ risk, study endpoints & create historical control for future clinical trials. TY to all of our participants for your commitment! #NFAwarenessMonth #EndNF
0
0
3
RT @AlexionPharma: While commonly recognized in early childhood, #Neurofibromatosis type 1 (NF1) is a lifelong, progressive condition that….
0
1
0
In honor of NF Awareness Month, we celebrate the legacy of a true pioneer. Dr. Riccardi’s contributions to the NF1 community have left an indelible mark on the field. Read more here.
0
1
8
Today is World NF Day. Neurofibromatosis type 1 (NF1) affects 1 in every 2,500 people worldwide. But most have never heard of it. That’s not just a gap in awareness — it’s a gap in funding, research, and treatment. At NTAP, we exist to close that gap - faster. #NFAwarenessMonth
1
4
8
Congratulations @BettegowdaMDPHD !.
Announcement: This just in! @BettegowdaMDPHD, the Jennison & Novak Families Professor of Neurosurgery, will lead the Johns Hopkins Department of Neurosurgery, as of 5/15. Henry Brem, MD, is stepping down after 25 years at the helm & we look forward to honoring him.
0
0
0
RT @ChildrensTumor: Got questions about NF? 🧠✨ In CTF’s all-new Big Questions about NF video series, CTF's Kate Kelts, RN, BSN, answers the….
0
1
0
RT @AlexionPharma: We're committed to raising awareness of #Neurofibromatosis during #NFAwarenessMonth in May and throughout the year. Re-s….
0
1
0
May is NF Awareness Month! We're proud to stand with the incredible NF community in raising awareness, driving research, and accelerating treatments for neurofibromatosis. #EndNF #fundNFresearch #MakeNFVisible
0
3
7
Such an important conversation!.Drug repositioning could be the breakthrough rare disease patients have been waiting for. #EndNF.
Tomorrow at #WODC2025, CTF CEO Dr. Annette Bakker moderates a keynote on drug repositioning—reviving shelved assets to treat rare diseases. 🔗 #DrugRepositioning #RareDisease #EndNF.
0
0
1
This is big news for the NF1 community. A reminder of what’s possible when research, regulatory, and patient advocacy worlds work together. Let’s keep working together and pushing for better!.#RareDisease #endNF #FDAApproval #NF1 #DrugDevelopment #Innovation #ClinicalTrials.
In February the FDA officially approved mirdametinib (Gomekli, SpringWorks Therapeutics) for adults and children (ages 2+) with NF1 and symptomatic plexiform neurofibromas. This new treatment option brings hope to those battling NF1! .Read more here!
0
3
5
RT @CavsCare: As we get ready to host our 3rd Annual Bow Tie Night tomorrow, learn more about Neurofibromatosis, or NF. LEARN MORE: https….
0
9
0